{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:02:33Z","timestamp":1793674953220,"version":"4.5.1"},"reference-count":183,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1751,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1111\/j.1478-3231.2010.02369.x","type":"journal-article","created":{"date-parts":[[2010,11,15]],"date-time":"2010-11-15T05:16:22Z","timestamp":1289798182000},"page":"146-162","source":"Crossref","is-referenced-by-count":247,"title":["Angiogenesis in chronic liver disease and its complications"],"prefix":"10.1111","volume":"31","author":[{"given":"Stephanie","family":"Coulon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femke","family":"Heindryckx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Geerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Van Steenkiste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Colle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Van Vlierberghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,11,15]]},"reference":[{"issue":"(S","key":"10.1111\/j.1478-3231.2010.02369.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0168-8278(02)00427-0","article-title":"The management of alcoholic liver disease","volume":"38","author":"Stewart","year":"2003","journal-title":"J Hepatol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1177\/026119290102900324","article-title":"Pyruvate-induced long-term maintenance of glutathione s-transferase in rat hepatocyte cultures","volume":"29","author":"Vanhaecke","year":"2001","journal-title":"Altern Lab Anim"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1053\/j.gastro.2009.08.068","article-title":"Role of placental growth factor in mesenteric neoangiogenesis in a mouse model of portal hypertension","volume":"137","author":"Van Steenkiste","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB4|cit4","first-page":"889","article-title":"Increased angiogenesis and permeability in the mesenteric microvasculature of rats with cirrhosis and portal hypertension","volume":"26","author":"Geerts","year":"2006","journal-title":"an in vivo study"},{"issue":"(S","key":"10.1111\/j.1478-3231.2010.02369.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S1665-2681(19)31820-4","article-title":"Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD)","volume":"8","author":"Bellentani","year":"2009","journal-title":"Ann Hepatol"},{"issue":"(S","key":"10.1111\/j.1478-3231.2010.02369.x-BIB6|cit6","first-page":"S17","article-title":"Pathophysiology of nonalcoholic steatohepatitis","volume":"40","author":"McCullough","year":"2006","journal-title":"J Clin Gastroenterol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"13459","DOI":"10.1073\/pnas.192342099","article-title":"Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor","volume":"99","author":"Ivan","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"38458","DOI":"10.1074\/jbc.M406026200","article-title":"Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor","volume":"279","author":"Appelhoff","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1439-0264.2010.01005.x","article-title":"Detection of hypoxia inducible factors and angiogenic growth factors during foetal endochondral and intramembranous ossification","volume":"39","author":"De Spiegelaere","year":"2010","journal-title":"Anat Histol Embryol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0945-053X(00)00123-2","article-title":"Cell density regulates prolyl 4-hydroxylase activity independent of mRNA levels","volume":"19","author":"Lee","year":"2001","journal-title":"Matrix Biol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1023\/A:1016076121918","article-title":"Fibrin fragment E stimulates the proliferation, migration and differentiation of human microvascular endothelial cells in vitro","volume":"4","author":"Bootle-Wilbraham","year":"2001","journal-title":"Angiogenesis"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s003920050472","article-title":"Regulation of the endothelial function and angiogenesis by vascular endothelial growth factor-A (VEGF-A)","volume":"89","author":"Kroll","year":"2000","journal-title":"Z Kardiol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.pupt.2005.02.007","article-title":"The biology of vascular endothelial growth factor-B (VEGF-B)","volume":"19","author":"Nash","year":"2006","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"E29","DOI":"10.1161\/01.RES.86.2.e29","article-title":"Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia","volume":"86","author":"Bellomo","year":"2000","journal-title":"Circ Res"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1002\/art.11232","article-title":"Vegfb gene knockout mice display reduced pathology and synovial angiogenesis in both antigen-induced and collagen-induced models of arthritis","volume":"48","author":"Mould","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.1128\/MCB.02214-07","article-title":"Deletion of vascular endothelial growth factor C (VEGF-C) and VEGF-D is not equivalent to VEGF receptor 3 deletion in mouse embryos","volume":"28","author":"Haiko","year":"2008","journal-title":"Mol Cell Biol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/ni1013","article-title":"Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins","volume":"5","author":"Karkkainen","year":"2004","journal-title":"Nat Immunol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1126\/science.276.5317.1423","article-title":"Hyperplasia of lymphatic vessels in VEGF-C transgenic mice","volume":"276","author":"Jeltsch","year":"1997","journal-title":"Science"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1365-2362.2005.01555.x","article-title":"VEGF-A, VEGF-D and VEGF-D(DeltaNDeltaC) induced intimal hyperplasia in carotid arteries","volume":"35","author":"Bhardwaj","year":"2005","journal-title":"Eur J Clin Invest"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1530\/eje.1.01843","article-title":"Correlation of VEGF production with IL1 alpha and IL6 secretion by human pituitary adenoma cells","volume":"152","author":"Borg","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0092-8674(00)81402-6","article-title":"Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor","volume":"92","author":"Soker","year":"1998","journal-title":"Cell"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/nm884","article-title":"Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1","volume":"9","author":"Autiero","year":"2003","journal-title":"Nat Med"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/87904","article-title":"Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions","volume":"7","author":"Carmeliet","year":"2001","journal-title":"Nat Med"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB24|cit24","first-page":"159","article-title":"Fibroblast growth factors as angiogenesis factors","volume":"79","author":"Klein","year":"1997","journal-title":"new insights into their mechanism of action"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0378-1119(01)00518-2","article-title":"Identification of a new fibroblast growth factor receptor, FGFR5","volume":"271","author":"Sleeman","year":"2001","journal-title":"Gene"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"23347","DOI":"10.1074\/jbc.272.37.23347","article-title":"Phosphatidylinositol 3\u2032-kinase-independent p70 S6 kinase activation by fibroblast growth factor receptor-1 is important for proliferation but not differentiation of endothelial cells","volume":"272","author":"Kanda","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"26523","DOI":"10.1074\/jbc.274.37.26523","article-title":"Molecular cloning, expression, and characterization of angiopoietin-related protein. Angiopoietin-related protein induces endothelial cell sprouting","volume":"274","author":"Kim","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3109\/08977199209046408","article-title":"Platelet-derived growth factor is angiogenic in vivo","volume":"7","author":"Risau","year":"1992","journal-title":"Growth Factors"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1006\/dbio.1994.1191","article-title":"Modulation of angiogenesis in vitro by laminin-entactin complex","volume":"164","author":"Nicosia","year":"1994","journal-title":"Dev Biol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1172\/JCI116936","article-title":"Modulation of platelet-derived growth factor receptor expression in microvascular endothelial cells during in vitro angiogenesis","volume":"93","author":"Marx","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/aja.1001990302","article-title":"Expression of the platelet-derived growth factor beta receptor during organogenesis and tissue differentiation in the mouse embryo","volume":"199","author":"Shinbrot","year":"1994","journal-title":"Dev Dyn"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"10238","DOI":"10.1016\/S0021-9258(18)86937-X","article-title":"Different effects of platelet-derived growth factor isoforms on rat vascular smooth muscle cells","volume":"265","author":"Sachinidis","year":"1990","journal-title":"J Biol Chem"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1172\/JCI115667","article-title":"Platelet-derived growth factor receptors on macrovascular endothelial cells mediate relaxation via nitric oxide in rat aorta","volume":"89","author":"Cunningham","year":"1992","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/978-3-540-78281-0_7","article-title":"PDGF and vessel maturation","volume":"180","author":"Hellberg","year":"2010","journal-title":"Recent Results Cancer Res"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB35|cit35","first-page":"651","article-title":"Integrins and angiogenesis","volume":"312","author":"Serini","year":"2006","journal-title":"a sticky business"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1128\/MCB.20.3.755-759.2000","article-title":"Normal development, wound healing, and adenovirus susceptibility in beta5-deficient mice","volume":"20","author":"Huang","year":"2000","journal-title":"Mol Cell Biol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm0102-27","article-title":"Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins","volume":"8","author":"Reynolds","year":"2002","journal-title":"Nat Med"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/0955-0674(95)80104-9","article-title":"Signal transduction of beta-catenin","volume":"7","author":"Gumbiner","year":"1995","journal-title":"Curr Opin Cell Biol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.cub.2009.02.057","article-title":"VE-Cadherin-mediated cell-cell interaction suppresses sprouting via signaling to MLC2 phosphorylation","volume":"19","author":"Abraham","year":"2009","journal-title":"Curr Biol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1083\/jcb.118.6.1511","article-title":"A novel endothelial-specific membrane protein is a marker of cell-cell contacts","volume":"118","author":"Lampugnani","year":"1992","journal-title":"J Cell Biol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"15099","DOI":"10.1074\/jbc.273.24.15099","article-title":"Vascular permeability factor\/vascular endothelial cell growth factor-mediated permeability occurs through disorganization of endothelial junctional proteins","volume":"273","author":"Kevil","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB42|cit42","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1083\/jcb.138.3.707","article-title":"CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells","volume":"138","author":"Dawson","year":"1997","journal-title":"J Cell Biol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"R136","DOI":"10.1186\/bcr620","article-title":"Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status","volume":"5","author":"Wang-Rodriguez","year":"2003","journal-title":"Breast Cancer Res"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB44|cit44","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/jcp.20904","article-title":"Thrombospondin-1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor-related protein-1 (LRP-1)","volume":"210","author":"Greenaway","year":"2007","journal-title":"J Cell Physiol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB45|cit45","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1007\/s11064-010-0159-6","article-title":"Induction of vascular endothelial growth factor and matrix metalloproteinase-9 via CD47 signaling in neurovascular cells","volume":"35","author":"Xing","year":"2010","journal-title":"Neurochem Res"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB46|cit46","doi-asserted-by":"crossref","first-page":"11721","DOI":"10.1074\/jbc.274.17.11721","article-title":"Endostatin induces endothelial cell apoptosis","volume":"274","author":"Dhanabal","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB47|cit47","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.1073\/pnas.95.10.5579","article-title":"Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD","volume":"95","author":"Claesson-Welsh","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB48|cit48","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000025623","article-title":"Angiostatin diminishes activation of the mitogen-activated protein kinases ERK-1 and ERK-2 in human dermal microvascular endothelial cells","volume":"36","author":"Redlitz","year":"1999","journal-title":"J Vasc Res"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB49|cit49","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nm0603-653","article-title":"Angiogenesis in health and disease","volume":"9","author":"Carmeliet","year":"2003","journal-title":"Nat Med"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB50|cit50","first-page":"G1169","article-title":"Cell adhesion and migration. III. Leukocyte adhesion and transmigration in the liver vasculature","volume":"273","author":"Jaeschke","year":"1997","journal-title":"Am J Physiol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB51|cit51","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/hep.510260617","article-title":"Role of Kupffer cells in gut ischemia\/reperfusion-induced hepatic microvascular dysfunction in mice","volume":"26","author":"Horie","year":"1997","journal-title":"Hepatology"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB52|cit52","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1023\/A:1023781114568","article-title":"Role of MAP kinase in tumor progression and invasion","volume":"22","author":"Reddy","year":"2003","journal-title":"Cancer Metastasis Rev"},{"issue":"(S","key":"10.1111\/j.1478-3231.2010.02369.x-BIB53|cit53","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1186\/1471-2105-11-S1-S32","article-title":"Detection of characteristic sub pathway network for angiogenesis based on the comprehensive pathway network","volume":"11","author":"Huang","year":"2010","journal-title":"BMC Bioinformatics"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB54|cit54","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nrc2397","article-title":"Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response","volume":"8","author":"Dewhirst","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB55|cit55","first-page":"1809","article-title":"Nuclear factor kappaB dependency of platelet-activating factor-induced angiogenesis","volume":"62","author":"Ko","year":"2002","journal-title":"Cancer Res"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB56|cit56","doi-asserted-by":"crossref","first-page":"6492","DOI":"10.4049\/jimmunol.154.12.6492","article-title":"Platelet-activating factor directly stimulates in vitro migration of endothelial cells and promotes in vivo angiogenesis by a heparin-dependent mechanism","volume":"154","author":"Camussi","year":"1995","journal-title":"J Immunol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB57|cit57","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1007\/s10620-006-9082-8","article-title":"The complex functions of mast cells in chronic human liver diseases","volume":"51","author":"Franceschini","year":"2006","journal-title":"Dig Dis Sci"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB58|cit58","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1046\/j.1365-2222.2001.01041.x","article-title":"Mast cells and angiogenesis","volume":"31","author":"Levi-Schaffer","year":"2001","journal-title":"Clin Exp Allergy"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB59|cit59","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1053\/j.gastro.2004.04.062","article-title":"Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes","volume":"127","author":"Safadi","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB60|cit60","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/hep.20965","article-title":"Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells","volume":"42","author":"Aleffi","year":"2005","journal-title":"Hepatology"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB61|cit61","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/hep.510310122","article-title":"Hypoxic stimulation of vascular endothelial growth factor expression in activated rat hepatic stellate cells","volume":"31","author":"Ankoma-Sey","year":"2000","journal-title":"Hepatology"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB62|cit62","first-page":"G143","article-title":"ET-1 induced alterations of hepatic microcirculation","volume":"267","author":"Bauer","year":"1994","journal-title":"sinusoidal and extrasinusoidal sites of action"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB63|cit63","first-page":"G269","article-title":"Vessel- and target cell-specific actions of endothelin-1 and endothelin-3 in rat liver","volume":"269","author":"Zhang","year":"1995","journal-title":"Am J Physiol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB64|cit64","doi-asserted-by":"crossref","first-page":"d1899","DOI":"10.2741\/A887","article-title":"Chemokines in liver inflammation and fibrosis","volume":"7","author":"Marra","year":"2002","journal-title":"Front Biosci"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB65|cit65","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/nm0206-171","article-title":"Angiogenesis and inflammation face off","volume":"12","author":"Imhof","year":"2006","journal-title":"Nat Med"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB66|cit66","first-page":"47","article-title":"Chemokines in the pathogenesis of liver disease","volume":"104","author":"Simpson","year":"2003","journal-title":"so many players with poorly defined roles"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB67|cit67","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/S0022-3565(24)38305-3","article-title":"Hepatic artery flow and propranolol metabolism in perfused cirrhotic rat liver","volume":"289","author":"Le Couteur","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB68|cit68","doi-asserted-by":"crossref","first-page":"G1187","DOI":"10.1152\/ajpgi.00229.2006","article-title":"Rat liver endothelial cells isolated by anti-CD31 immunomagnetic separation lack fenestrae and sieve plates","volume":"291","author":"DeLeve","year":"2006","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB69|cit69","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.2353\/ajpath.2007.060887","article-title":"Proangiogenic cytokines as hypoxia-dependent factors stimulating migration of human hepatic stellate cells","volume":"170","author":"Novo","year":"2007","journal-title":"Am J Pathol"},{"issue":"(S","key":"10.1111\/j.1478-3231.2010.02369.x-BIB70|cit70","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1111\/j.1440-1746.2006.04663.x","article-title":"Blockade of renin-angiotensin system in antifibrotic therapy","volume":"22","author":"Yoshiji","year":"2007","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB71|cit71","first-page":"98","article-title":"Mechanisms of disease","volume":"1","author":"Friedman","year":"2004","journal-title":"mechanisms of hepatic fibrosis and therapeutic implications"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB72|cit72","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1055\/s-2001-17553","article-title":"Transcriptional regulation in hepatic stellate cells","volume":"21","author":"Eng","year":"2001","journal-title":"Semin Liver Dis"},{"issue":"(S","key":"10.1111\/j.1478-3231.2010.02369.x-BIB73|cit73","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1111\/j.1440-1746.2006.04585.x","article-title":"Transcriptional regulation of stellate cell activation","volume":"21","author":"Friedman","year":"2006","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB74|cit74","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1096\/fasebj.11.6.9194526","article-title":"The codependence of angiogenesis and chronic inflammation","volume":"11","author":"Jackson","year":"1997","journal-title":"FASEB J"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB75|cit75","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1053\/jhep.2000.18658","article-title":"Inhibition of hepatic stellate cell proliferation and activation by the semisynthetic analogue of fumagillin TNP-470 in rats","volume":"32","author":"Wang","year":"2000","journal-title":"Hepatology"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB76|cit76","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1136\/gut.52.9.1347","article-title":"Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis","volume":"52","author":"Yoshiji","year":"2003","journal-title":"Gut"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB77|cit77","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1002\/hep.21921","article-title":"Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats","volume":"46","author":"Tugues","year":"2007","journal-title":"Hepatology"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB78|cit78","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1111\/j.1872-034X.2008.00369.x","article-title":"Rapamycin prevents mesenteric neo-angiogenesis and reduces splanchnic blood flow in portal hypertensive mice","volume":"38","author":"Geerts","year":"2008","journal-title":"Hepatol Res"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB79|cit79","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/hep.20828","article-title":"The potential of angiogenesis soluble markers in chronic hepatitis C","volume":"42","author":"Salcedo","year":"2005","journal-title":"Hepatology"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB80|cit80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0889-8553(21)00175-8","article-title":"Pathophysiology of portal hypertension","volume":"21","author":"Bosch","year":"1992","journal-title":"Gastroenterol Clin North Am"},{"issue":"(S","key":"10.1111\/j.1478-3231.2010.02369.x-BIB81|cit81","first-page":"231","article-title":"Pathophysiology of portal hypertension","volume":"59","author":"Cichoz-Lach","year":"2008","journal-title":"J Physiol Pharmacol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB82|cit82","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jhep.2005.02.022","article-title":"Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats","volume":"43","author":"Fernandez","year":"2005","journal-title":"J Hepatol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB83|cit83","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.21785","article-title":"Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats","volume":"46","author":"Fernandez","year":"2007","journal-title":"Hepatology"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB84|cit84","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1136\/gut.2005.088013","article-title":"NAD(P)H oxidase modulates angiogenesis and the development of portosystemic collaterals and splanchnic hyperaemia in portal hypertensive rats","volume":"56","author":"Angermayr","year":"2007","journal-title":"Gut"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB85|cit85","first-page":"44","article-title":"Inflammation","volume":"4","author":"Aller","year":"2007","journal-title":"a way to understanding the evolution of portal hypertension"},{"issue":"(S","key":"10.1111\/j.1478-3231.2010.02369.x-BIB86|cit86","first-page":"S39","article-title":"Fat distribution and storage","volume":"157","author":"Weiss","year":"2007","journal-title":"how much, where, and how?"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB87|cit87","first-page":"75","article-title":"Pathogenesis of non-alcoholic steatohepatitis","volume":"11","author":"Edmison","year":"2007","journal-title":"human data"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB88|cit88","first-page":"842","article-title":"Steatohepatitis","volume":"114","author":"Day","year":"1998","journal-title":"a tale of two \u2018hits\u2019?"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB89|cit89","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.cld.2009.07.009","article-title":"Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis","volume":"13","author":"Cusi","year":"2009","journal-title":"Clin Liver Dis"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB90|cit90","first-page":"23","article-title":"Review article","volume":"22","author":"Salcedo","year":"2005","journal-title":"angiogenesis soluble factors as liver disease markers"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB91|cit91","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/hep.20302","article-title":"Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice","volume":"40","author":"McCuskey","year":"2004","journal-title":"Hepatology"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB92|cit92","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/hep.21338","article-title":"Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats","volume":"44","author":"Kitade","year":"2006","journal-title":"Hepatology"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB93|cit93","first-page":"212","article-title":"Gene expression in obese patients with non-alcoholic steatohepatitis","volume":"100","author":"Cayon","year":"2008","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB94|cit94","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.3748\/wjg.15.5193","article-title":"Crosstalk between angiogenesis, cytokeratin-18, and insulin resistance in the progression of non-alcoholic steatohepatitis","volume":"15","author":"Kitade","year":"2009","journal-title":"World J Gastroenterol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB95|cit95","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1111\/j.1349-7006.2001.tb02141.x","article-title":"Relationship of the microvascular type to the tumor size, arterialization and dedifferentiation of human hepatocellular carcinoma","volume":"92","author":"Yamamoto","year":"2001","journal-title":"Jpn J Cancer Res"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB96|cit96","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1309\/FXNL-QTN1-94FH-AB3A","article-title":"Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1\/KDR in hepatocellular carcinoma","volume":"116","author":"Ng","year":"2001","journal-title":"Am J Clin Pathol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB97|cit97","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0092-8674(00)80108-7","article-title":"Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis","volume":"86","author":"Hanahan","year":"1996","journal-title":"Cell"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB98|cit98","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1126\/science.7521539","article-title":"Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1","volume":"265","author":"Dameron","year":"1994","journal-title":"Science"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB99|cit99","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1349-7006.1996.tb00244.x","article-title":"Sinusoidal capillarization and arterial blood supply continuously proceed with the advance of the stages of hepatocarcinogenesis in the rat","volume":"87","author":"Yamamoto","year":"1996","journal-title":"Jpn J Cancer Res"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB100|cit100","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.toxlet.2009.04.013","article-title":"Hepatocyte growth factor, vascular endothelial growth factor, glial cell-derived neurotrophic factor and nerve growth factor are differentially affected by early chronic ethanol or red wine intake","volume":"188","author":"Fiore","year":"2009","journal-title":"Toxicol Lett"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB101|cit101","first-page":"61","article-title":"Innovative use of the vascular endothelial growth factor in an experimental model of acute liver failure","volume":"25","author":"Marino","year":"2004","journal-title":"G Chir"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB102|cit102","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.5858\/2000-124-1061-IEOVEG","article-title":"Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis","volume":"124","author":"Park","year":"2000","journal-title":"Arch Pathol Lab Med"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB103|cit103","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jhep.2004.03.001","article-title":"Involvement of the vascular endothelial growth factor receptor-1 in murine hepatocellular carcinoma development","volume":"41","author":"Yoshiji","year":"2004","journal-title":"J Hepatol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB104|cit104","first-page":"1835","article-title":"High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma","volume":"14","author":"Poon","year":"2007","journal-title":"importance of tumor biomarker in ablative therapies"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB105|cit105","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1365-2893.2006.00782.x","article-title":"Increased expression of vascular endothelial growth factor in small hepatocellular carcinoma","volume":"14","author":"Iavarone","year":"2007","journal-title":"J Viral Hepat"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB106|cit106","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1245\/ASO.2003.08.924","article-title":"Prognostic value of plasma and serum VEGF levels in patients with resectable hepatocellular carcinoma","volume":"10","author":"Ferrero","year":"2003","journal-title":"Ann Surg Oncol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB107|cit107","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1245\/ASO.2003.10.002","article-title":"Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery","volume":"10","author":"Chao","year":"2003","journal-title":"Ann Surg Oncol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB108|cit108","first-page":"414","article-title":"Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma","volume":"26","author":"Wada","year":"2006","journal-title":"importance of angiopoietin-2 and hypoxia-induced factor-1 alpha"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB109|cit109","first-page":"220","article-title":"Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma","volume":"4","author":"Yao","year":"2005","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB110|cit110","first-page":"1705","article-title":"Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in hepatocellular carcinoma","volume":"11","author":"Huang","year":"2005","journal-title":"impact on neovascularization and survival"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB111|cit111","first-page":"327","article-title":"Prognostic factors and recurrence of small hepatocellular carcinoma after hepatic resection or microwave ablation","volume":"12","author":"Wang","year":"2008","journal-title":"a retrospective study"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB112|cit112","first-page":"772","article-title":"Vascular endothelial growth factor expression in serum of patients with hepatocellular carcinoma","volume":"116","author":"Zhao","year":"2003","journal-title":"Chin Med J"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB113|cit113","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.3748\/wjg.v10.i10.1533","article-title":"Effect of c-myc, Ki-67, MMP-2 and VEGF expression on prognosis of hepatocellular carcinoma patients undergoing tumor resection","volume":"10","author":"Cui","year":"2004","journal-title":"World J Gastroenterol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB114|cit114","first-page":"643","article-title":"Prognostic significance of preoperative circulating vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma","volume":"10","author":"Jeng","year":"2004","journal-title":"a prospective study"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB115|cit115","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/hep.510280111","article-title":"Expression of vascular endothelial growth factor in human hepatocellular carcinoma","volume":"28","author":"Yamaguchi","year":"1998","journal-title":"Hepatology"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB116|cit116","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jso.21095","article-title":"Correlations of the expression of vascular endothelial growth factor B and its isoforms in hepatocellular carcinoma with clinico-pathological parameters","volume":"98","author":"Kanda","year":"2008","journal-title":"J Surg Oncol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB117|cit117","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.canlet.2006.10.005","article-title":"Placenta growth factor not vascular endothelial growth factor A or C can predict the early recurrence after radical resection of hepatocellular carcinoma","volume":"250","author":"Ho","year":"2007","journal-title":"Cancer Lett"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB118|cit118","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.cell.2010.02.039","article-title":"Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease","volume":"141","author":"Van de Veire","year":"2010","journal-title":"Cell"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB119|cit119","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s004320050009","article-title":"Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus","volume":"126","author":"Zhou","year":"2000","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB120|cit120","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/jso.1129","article-title":"Multidrug resistance gene (MDR-1) expression as a useful prognostic factor in patients with human hepatocellular carcinoma after surgical resection","volume":"78","author":"Kato","year":"2001","journal-title":"J Surg Oncol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB121|cit121","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0304-3835(98)00280-8","article-title":"The study of innate drug resistance of human hepatocellular carcinoma Bel7402 cell line","volume":"135","author":"Huang","year":"1999","journal-title":"Cancer Lett"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB122|cit122","first-page":"S109","article-title":"Hepatocellular carcinoma","volume":"35","author":"Di Maio","year":"2002","journal-title":"systemic treatments"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB123|cit123","first-page":"1182","article-title":"Tumor angiogenesis","volume":"285","author":"Folkman","year":"1971","journal-title":"therapeutic implications"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB124|cit124","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1478-3231.2008.01762.x","article-title":"Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model","volume":"29","author":"Finn","year":"2009","journal-title":"Liver Int"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB125|cit125","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1111\/j.1582-4934.2009.00692.x","article-title":"Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma","volume":"13","author":"Huynh","year":"2009","journal-title":"J Cell Mol Med"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB126|cit126","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","article-title":"Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5","volume":"66","author":"Liu","year":"2006","journal-title":"Cancer Res"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB127|cit127","first-page":"739","article-title":"Sorafenib therapy in advanced hepatocellular carcinoma","volume":"9","author":"Rimassa","year":"2009","journal-title":"the SHARP trial"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB128|cit128","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1200\/JCO.2007.15.9947","article-title":"Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma","volume":"26","author":"Siegel","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB129|cit129","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/S1470-2045(06)70980-9","article-title":"Splenic infarction and bevacizumab","volume":"7","author":"Malka","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB130|cit130","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1200\/JCO.2005.04.9130","article-title":"Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma","volume":"24","author":"Zhu","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB131|cit131","article-title":"Bevacizumab enhances chemosensitivity of hepatocellular carcinoma to adriamycin related to inhibition of survivin expression","author":"Xiong","year":"2010","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB132|cit132","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/sj.bjc.6605580","article-title":"Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma","volume":"102","author":"Hsu","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB133|cit133","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.3748\/wjg.v16.i28.3592","article-title":"Sustained treatment response of metastatic hepatocellular carcinoma with bevacizumab and sorafenib","volume":"16","author":"Wich","year":"2010","journal-title":"World J Gastroenterol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB134|cit134","first-page":"1774","article-title":"SU14813","volume":"5","author":"Patyna","year":"2006","journal-title":"a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB135|cit135","first-page":"327","article-title":"In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors","volume":"9","author":"Mendel","year":"2003","journal-title":"determination of a pharmacokinetic\/pharmacodynamic relationship"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB136|cit136","first-page":"263","article-title":"Development of sunitinib in hepatocellular carcinoma","volume":"15","author":"Zhu","year":"2009","journal-title":"rationale, early clinical experience, and correlative studies"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB137|cit137","first-page":"3027","article-title":"Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma","volume":"27","author":"Zhu","year":"2009","journal-title":"a phase II study"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB138|cit138","first-page":"794","article-title":"Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma","volume":"10","author":"Faivre","year":"2009","journal-title":"an open-label, multicentre, phase II study"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB139|cit139","first-page":"285","article-title":"Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma","volume":"15","author":"Koeberle","year":"2010","journal-title":"a Swiss group for clinical cancer research (SAKK) and Swiss association for the study of the liver (SASL) multicenter phase II trial (SAKK 77\/06)"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB140|cit140","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.bcp.2005.11.005","article-title":"ZD6474 inhibits proliferation and invasion of human hepatocellular carcinoma cells","volume":"71","author":"Giannelli","year":"2006","journal-title":"Biochem Pharmacol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB141|cit141","doi-asserted-by":"crossref","first-page":"6146","DOI":"10.1158\/1078-0432.CCR-08-0509","article-title":"Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma","volume":"14","author":"Huynh","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB142|cit142","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1158\/1078-0432.CCR-10-0574","article-title":"A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2","volume":"16","author":"Eder","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB143|cit143","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jhep.2009.10.008","article-title":"AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC)","volume":"52","author":"Huynh","year":"2010","journal-title":"J Hepatol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB144|cit144","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1158\/1535-7163.MCT-06-0436","article-title":"Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma","volume":"6","author":"Huynh","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB145|cit145","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1517\/14656561003724705","article-title":"Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib","volume":"11","author":"Yau","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB146|cit146","first-page":"4389","article-title":"AZD2171","volume":"65","author":"Wedge","year":"2005","journal-title":"a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB147|cit147","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1517\/14728210903571659","article-title":"Tyrosine kinase inhibitors to treat liver cancer","volume":"15","author":"Huynh","year":"2010","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB148|cit148","first-page":"2546","article-title":"Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171)","volume":"8","author":"Morelli","year":"2009","journal-title":"effects on migration and invasion of gastrointestinal cancer cell lines"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB149|cit149","doi-asserted-by":"crossref","first-page":"6657","DOI":"10.1200\/JCO.2005.14.696","article-title":"Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer","volume":"23","author":"Philip","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB150|cit150","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1200\/JCO.2008.18.3301","article-title":"Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma","volume":"27","author":"Thomas","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB151|cit151","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/cncr.22886","article-title":"Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma","volume":"110","author":"Thomas","year":"2007","journal-title":"Cancer"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB152|cit152","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00280-009-0927-7","article-title":"A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer","volume":"64","author":"Ramanathan","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB153|cit153","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1111\/j.1478-3231.2010.02239.x","article-title":"Gefitinib as an effective therapy for advanced hepatocellular carcinoma with lung metastasis?","volume":"30","author":"Chen","year":"2010","journal-title":"Liver Int"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB154|cit154","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/hep.20538","article-title":"Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis","volume":"41","author":"Schiffer","year":"2005","journal-title":"Hepatology"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB155|cit155","doi-asserted-by":"crossref","first-page":"370","DOI":"10.4143\/crt.2005.37.6.370","article-title":"Gefitinib trial in a Fanconi's anemia patient with multiple squamous cell carcinomas and hepatocellular carcinoma","volume":"37","author":"Jung","year":"2005","journal-title":"Cancer Res Treat"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB156|cit156","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/cncr.22829","article-title":"Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma","volume":"110","author":"Zhu","year":"2007","journal-title":"Cancer"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB157|cit157","first-page":"1384","article-title":"Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC)","volume":"109","author":"Louafi","year":"2007","journal-title":"results of a phase II study"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB158|cit158","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jhep.2009.03.028","article-title":"Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo","volume":"51","author":"Newell","year":"2009","journal-title":"J Hepatol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB159|cit159","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1053\/j.gastro.2008.08.008","article-title":"Pivotal role of mTOR signaling in hepatocellular carcinoma","volume":"135","author":"Villanueva","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB160|cit160","first-page":"247","article-title":"mTOR inhibitors for hepatocellular cancer","volume":"9","author":"Treiber","year":"2009","journal-title":"a forward-moving target"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB161|cit161","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s10147-007-0733-3","article-title":"Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer","volume":"13","author":"Rizell","year":"2008","journal-title":"Int J Clin Oncol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB162|cit162","doi-asserted-by":"crossref","first-page":"8421","DOI":"10.1158\/1078-0432.CCR-04-0941","article-title":"mTOR and P70 S6 kinase expression in primary liver neoplasms","volume":"10","author":"Sahin","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB163|cit163","first-page":"789","article-title":"Inhibition of mTOR suppresses experimental liver tumours","volume":"25","author":"Rizell","year":"2005","journal-title":"Anticancer Res"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB164|cit164","first-page":"509","article-title":"Effect of thalidomide in hepatocellular carcinoma","volume":"235","author":"Hsu","year":"2005","journal-title":"assessment with power doppler US and analysis of circulating angiogenic factors"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB165|cit165","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000074477","article-title":"Low-dose thalidomide treatment for advanced hepatocellular carcinoma","volume":"65","author":"Hsu","year":"2003","journal-title":"Oncology"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB166|cit166","first-page":"1012","article-title":"Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach","volume":"20","author":"Pinter","year":"2008","journal-title":"a phase I\/II trial"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB167|cit167","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1634\/theoncologist.10-9-718","article-title":"Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression","volume":"10","author":"Schwartz","year":"2005","journal-title":"Oncologist"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB168|cit168","first-page":"225","article-title":"Thalidomide for treating metastatic hepatocellular carcinoma","volume":"21","author":"Han","year":"2006","journal-title":"a pilot study"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB169|cit169","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1111\/j.1440-1746.2006.04303.x","article-title":"Low dose of thalidomide can be effective in advanced hepatocellular carcinoma","volume":"21","author":"Chen","year":"2006","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB170|cit170","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1007\/s00280-006-0203-z","article-title":"Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma","volume":"58","author":"Shiah","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB171|cit171","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1158\/1078-0432.CCR-09-0095","article-title":"Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy","volume":"15","author":"Ebos","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB172|cit172","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ccr.2009.01.021","article-title":"Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis","volume":"15","author":"Ebos","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB173|cit173","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ccr.2009.01.027","article-title":"Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis","volume":"15","author":"Paez-Ribes","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB174|cit174","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nrc2442","article-title":"Modes of resistance to anti-angiogenic therapy","volume":"8","author":"Bergers","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB175|cit175","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0093-7754(01)90211-8","article-title":"Biological consequences of tumor hypoxia","volume":"28","author":"Hockel","year":"2001","journal-title":"Semin Oncol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB176|cit176","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s00109-007-0281-3","article-title":"Hypoxia and cancer","volume":"85","author":"Brahimi-Horn","year":"2007","journal-title":"J Mol Med"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB177|cit177","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.cell.2009.01.020","article-title":"Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization","volume":"136","author":"Mazzone","year":"2009","journal-title":"Cell"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB178|cit178","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejphar.2009.12.014","article-title":"Baicalin suppresses lung carcinoma and lung metastasis by SOD mimic and HIF-1alpha inhibition","volume":"630","author":"Du","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB179|cit179","doi-asserted-by":"crossref","first-page":"H560","DOI":"10.1152\/ajpheart.00133.2005","article-title":"VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature","volume":"290","author":"Kamba","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB180|cit180","doi-asserted-by":"crossref","first-page":"17069","DOI":"10.1073\/pnas.0708148104","article-title":"Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy","volume":"104","author":"Ebos","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB181|cit181","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/nature04186","article-title":"VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche","volume":"438","author":"Kaplan","year":"2005","journal-title":"Nature"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB182|cit182","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1002\/hep.22506","article-title":"Molecular targeted therapies in hepatocellular carcinoma","volume":"48","author":"Llovet","year":"2008","journal-title":"Hepatology"},{"key":"10.1111\/j.1478-3231.2010.02369.x-BIB183|cit183","first-page":"1066","article-title":"Antiangiogenic therapy","volume":"49","author":"Shah","year":"2009","journal-title":"not just for cancer anymore?"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1478-3231.2010.02369.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1478-3231.2010.02369.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T21:03:04Z","timestamp":1740690184000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1478-3231.2010.02369.x"}},"subtitle":["Angiogenesis in CLD"],"short-title":[],"issued":{"date-parts":[[2010,11,15]]},"references-count":183,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1478-3231.2010.02369.x","relation":{},"ISSN":["1478-3223"],"issn-type":[{"value":"1478-3223","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11,15]]}}}